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ABSTRACT
Despite its limited pathogenicity, Stenotrophomonas maltophilia is an emerging nosocomial pathogen. This
study investigated the isolation frequency, antimicrobial resistance and genotypic relationships of 205
S. maltophilia isolates from 188 patients in a university hospital between 1998 and 2003. Susceptibility
profiles for 11 antimicrobial agents were determined by the NCCLS agar dilution method for non-
fermentative bacteria, while enterobacterial repetitive intergenic consensus sequence (ERIC)-PCR and
pulsed-field gel electrophoresis (PFGE) were used for genotyping of the isolates. Of the 205 isolates,
56.1% were isolated in the last 2 years of the study. The risk of S. maltophilia isolation was higher in
intensive care units, S. maltophilia was isolated mostly (86.8%) after hospitalisation for ‡ 48 h, and 90.4%
of the patients had underlying diseases. Resistance levels were > 60% for all antimicrobial agents tested
except co-trimoxazole. High genetic diversity was found among the S. maltophilia isolates, and cross-
infection with S. maltophilia was not common. Although ERIC-PCR revealed fewer genotypes than
PFGE, it proved to be a rapid and easy method for S. maltophilia genotyping, and was more economical
than PFGE.
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INTRODUCTION
Stenotrophomonas maltophilia is an opportunistic
pathogen of increasing importance. The use of
broad-spectrum antibiotics and an increase in the
number of invasive procedures and immuno-
suppressed patients has caused this intrinsic-
ally multidrug-resistant microorganism to
emerge as an infectious agent in hospitals,
especially in intensive care units (ICUs) [1–3].
Its resistance to many antimicrobial agents,
including b-lactams and aminoglycosides, allows
patient colonisation even when antimicrobial
agents are being used [4]. Despite its relatively
low virulence, S. maltophilia can cause a wide
variety of infections, e.g., pneumonia, bacter-
aemia, endocarditis, urinary tract infection,
meningitis, cholangitis, soft tissue infection and
wound infection [3–7]. Predisposing factors for
S. maltophilia infection include prolonged hospi-
talisation, especially in ICUs, consumption of
broad-spectrum antibiotics, malignancy, immune
suppression, and breakdown of mucocutaneous
defence barriers (e.g., following catheterisation,
artificial implants, tracheotomy, or peritoneal
dialysis) [8,9].
Epidemiological studies of clinical S. maltophilia
isolates have shown genetic diversity [10,11],
probably associated with selection of naturally
present S. maltophilia from among other bacteria
by antibiotic pressure. However, cross-infections
between patients, transmitted by healthcare
workers, have also been reported [12]. For this
reason, detection of antibiotic resistance patterns
and typing of S. maltophilia isolates is significant
in the context of hospital infection control. The
present study investigated antibiotic resistance
patterns and genotypes among S. maltophilia
isolates in a hospital for adults during the period
1998–2003.
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MATERIALS AND METHODS
Bacterial isolates
S. maltophilia isolates were obtained from various clinical
specimens at the Hacettepe University Faculty of Medicine
Adult Hospital, Clinical Pathology Laboratory between 1998
and 2003. In total, 205 isolates from 188 patients were
included in the study. Isolates from the same patient were
obtained from different anatomical sites. The isolates
were identified initially by the Sceptor (Becton-Dickinson,
Franklin Lakes, NJ, USA) system, and the identification was
confirmed by manual biochemical tests (Gram’s stain, cat-
alase, oxidase, aesculin hydrolysis, lysine decarboxylase and
DNase).
Antimicrobial susceptibility testing
Susceptibility to 11 antimicrobial agents (imipenem, merope-
nem, co-trimoxazole, amikacin, gentamicin, ciprofloxacin,
ceftazidime, cefepime, cefotaxime, piperacillin and piperacil-
lin–tazobactam) was determined by the NCCLS agar dilution
method for non-fermentative bacteria [13]. MICs were deter-
mined after incubation for 24 and 48 h on Mueller–Hinton
agar plates at 36C. Intermediately-resistant isolates
were considered to be resistant. Pseudomonas aeruginosa
ATCC 27853 and Escherichia coli ATCC 35218 (for piperacil-
lin–tazobactam) were included as quality control strains in
each run.
Enterobacterial repetitive intergenic consensus sequence
(ERIC)-PCR typing
The ERIC-PCR method used for genotyping S. maltophilia
isolates was optimised from previous studies [14,15]. A
single colony was inoculated into Mueller–Hinton broth and
incubated for 20 h at 37C. After centrifugation at 10 000 g
for 10 min, each pellet was washed three times in 750 lL TE
buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) and then
resuspended in 500 lL TE buffer. The solution was boiled
for 20 min and centrifuged at 10 000 g for 10 min, and the
supernatant was then used as a crude DNA extract in PCRs.
Amplification reactions were performed in a final volume of
25 lL, with 15.5 lL H2O, 2.5 lL 25 mM MgCl2, 2.0 lL each
2.5 mM dATP, dTTP, dGTP and dCTP, 0.3 lL 1 mM ERIC2
primer (5¢-AAGTAAGTGACTGGGGTGAGCG-3¢) (Trilink
Biotechnologies, San Diego, CA, USA), 2.6 lL 10· PCR
buffer (Sigma-Aldrich, Munich, Germany), 0.13 lL Taq
polymerase (Sigma-Aldrich) and 2 lL DNA extract. A
negative control with H2O instead of DNA extract was used
in each run. PCRs comprised one cycle for 3 min at 94C,
two cycles of 45 s at 94C, 1 min at 30C and 1 min at 72C,
and 44 cycles of 30 s at 94C, 30 s at 55C and 1 min at
72C, with a final extension for 4 min at 72C. The PCR
products were analysed by electrophoresis with DNA
Molecular Weight Marker XIV (Roche Diagnostics, Istanbul,
Turkey) for 2 h at 110 V in an agarose 1.5% w ⁄v gel and
staining with ethidium bromide 0.1% w ⁄v. The amplicon
patterns were evaluated with a Gel Documentation System
(UV Products, Upland, CA, USA). Differences of two or
more DNA bands were considered to represent different
strains, while isolates differing by only one band were
considered to be subtypes [11,16,17].
Pulsed-field gel electrophoresis (PFGE) analysis
Preparation of agarose plugs containing chromosomal DNA for
PFGE analysis was performed as described previously [18]. The
DNA contained in the plugs was digested with 20 U of XbaI
(Roche Diagnostics) at 37C overnight as recommended by the
manufacturer. The digested plugs and molecular size markers
(Pulse Marker 50–1000 kb; Sigma-Aldrich) were analysed by
PFGE in high gel strength agarose (Genaxis Biotechnology,
Spechbach, Germany) 1.1% w ⁄v gels in a GN Controller
(Amersham Pharmacia Biotech, Freiburg, Germany) with Tris-
borate-EDTA (TBE; 0.5 M Tris, 0.5 M boric acid, 0.01 M EDTA,
pH 8) buffer. PFGE was for 22 h at 150 V ⁄ cm at 12C, with a
pulse time that increased from 10 s to 90 s. The gel was stained
with ethidium bromide 0.1% w ⁄v and the DNA patterns were
evaluated using the UV Products Gel Documentation System.
The band patterns were interpreted according to the criteria of
Tenover et al. [19], with patterns that differed by two or three
bands being defined as closely related subtypes.
Statistics
Data were analysed with SPSS software for Windows (SPSS
Inc., Chicago, IL, USA) by the McNemar, chi-square and
Fisher–Freeman Halton tests, with p < 0.05 being considered
significant.
RESULTS
Isolates
The 205 S. maltophilia isolates were from 104 male
and 84 female patients. There was a gradually
increasing frequency of S. maltophilia isolation
during the study period. Of all non-fermentative
bacterial isolates, S. maltophilia accounted for
4.0%, 5.8% and 9.7% in 2001, 2002 and 2003,
respectively, with 56.1% of the isolates being
obtained during the last 2 years of the study. The
most frequent site of isolation was the respiratory
tract (40%), followed by blood (21.5%) and pus
(13.2%). S. maltophilia was the only microorgan-
ism isolated from 97 (47.3%) specimens. The other
infections were polymicrobial. Sixty-two of the
specimens yielded two organisms, 39 yielded
three, and seven yielded four. The most frequent
co-isolated microorganisms were P. aeruginosa
(24.7%), Staphylococcus aureus (20.1%), Klebsiella
spp. (12.1%) and Acinetobacter spp. (10.3%).
Only 12 (6.4%) of the patients were not hospi-
talised, and 178 (86.8%) of the 205 isolates were
obtained from patients after hospitalisation for
‡ 2 days (Table 1). Eighty-one (46%) patients
were in medical wards, 43 (24.4%) in surgical
wards, and 52 (29.6%) in ICUs. The greatest risk
for S. maltophilia isolation was in ICUs if the
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number of beds per unit was taken into consid-
eration. The mean duration of hospitalisation
before S. maltophilia was isolated was similar for
all wards (Table 1).
Patient records were available for all but 13
patients. In total, 170 (90.4%) of the patients from
whom S. maltophilia was isolated had underlying
diseases, and 134 (71.3%) had more than one
underlying disease. Malignant diseases were the
most common (35.1% of patients), followed by
hypertension (22.9%), obstructive lung disease
(20.2%) and diabetes mellitus (17.6%). One
patient without underlying disease had keratitis
caused by contamination of contact lenses.
Antimicrobial resistance
The resistance rates of the S. maltophilia isolates
were > 60% for all antimicrobial agents except
co-trimoxazole (Table 2). The differences between
resistance rates obtained after incubation for 24 h
and 48 h were significant for co-trimoxazole,
ciprofloxacin, ceftazidime, cefepime, piperacillin
and piperacillin–tazobactam (p < 0.05). The dif-
ferences in the MIC50 and MIC90 values after
incubation for 24 h and 48 hwere atmost two-fold,
except the MIC90 value for ciprofloxacin, which
increased four-fold. There were no significant
changes in the antimicrobial resistance rates dur-
ing the study period, except for imipenem
(p 0.0003), meropenem (p 0.005), co-trimoxazole
(p 0.0003), piperacillin (p 0.0001) and piperacillin–
tazobactam (p 0.0001) (Table 3).
Genotyping
Among the 205 isolates studied, ERIC-PCR analy-
sis revealed 180 genotypes and PFGE analysis
revealed 188 genotypes. Fifteen patients yielded
more than one isolate, but only eight of these
shared similar ERIC-PCR and PFGE patterns. The
isolates with similar patterns were isolated mostly
Table 1. Distribution of patients and mean duration of
hospitalisation before isolation of Stenotrophomonas malto-
philia
Patients
n (%)
Mean duration (days)
of hospitalisation
before isolation of
S. maltophilia
Medical wards 81 (46.0) 32.5
Surgical wards 43 (24.4) 39.6
Intensive care units
(medical and surgical)
52 (29.6) 38.3
Total 176 (100) 36.4
Table 2. Resistance of Stenotropho-
monas maltophilia isolates to 11 anti-
microbial agents
Antimicrobial
agent
MIC range
(mg ⁄L)
24 h 48 h
Resistant
isolates
n (%)
MIC50
(mg ⁄L)
MIC90
(mg ⁄L)
Resistant
isolates
n (%)
MIC50
(mg ⁄L)
MIC90
(mg ⁄L)
Imipenem 0.5–1024 202 (98.5) 512 512 203 (99.0) 512 1024
Meropenem 0.5–512 201 (98.0) 128 256 201 (98.0) 128 256
Co-trimoxazole 0.25 ⁄ 4.75–32 ⁄ 608 58 (28.3) 2 ⁄ 38 8 ⁄ 152 73 (35.6) 2 ⁄ 38 8 ⁄ 152
Amikacin 2–1024 174 (84.9) 128 512 176 (85.8) 128 512
Gentamicin 2–2048 194 (94.6) 128 512 196 (95.6) 128 512
Ciprofloxacin 0.5–256 189 (92.2) 4 8 199 (97.1) 4 32
Ceftazidime 1–512 146 (71.2) 32 256 153 (74.6) 64 256
Cefotaxime 1–512 196 (95.6) 128 256 197 (96.1) 128 256
Cefepime 2–128 126 (61.5) 16 32 159 (77.6) 16 32
Piperacillin 4–2048 184 (89.8) 128 1024 197 (96.1) 256 1024
Piperacillin–
tazobactam
2 ⁄ 4–1024 ⁄ 4 180 (87.8) 128 512 193 (94.2) 128 512
Table 3. Susceptibility of Stenotrophomonas maltophilia isolates to 11 antimicrobial agents during the study period (1998–
2003)
Year
(n)
IMP
(%)
MER
(%)
T ⁄ S
(%)
AK
(%)
GEN
(%)
CIP
(%)
CAZ
(%)
CTX
(%)
FEP
(%)
PIP
(%)
P ⁄T
(%)
1998 (16) 100.0 100.0 12.5 75.0 100.0 100.0 62.5 93.7 62.5 93.7 87.5
1999 (41) 100.0 100.0 58.5 82.9 90.2 90.2 68.3 97.6 56.1 82.9 97.6
2000 (15) 80.0 86.6 26.6 60.0 86.6 86.6 53.3 93.3 40.0 66.7 86.6
2001 (18) 100.0 100.0 16.6 88.8 94.4 94.4 72.2 83.3 55.5 50.0 50.0
2002 (42) 100.0 100.0 16.6 88.1 90.5 88.1 80.9 97.6 64.3 97.6 92.9
2003 (73) 100.0 100.0 24.6 89.0 98.6 95.9 71.2 97.3 68.5 90.4 76.7
Total 98.5 98.0 28.3 84.9 94.6 92.2 71.2 95.6 61.5 89.8 87.8
IMP, imipenem; MER, meropenem; T ⁄ S, co-trimoxazole; AK, amikacin; GEN, gentamicin; CIP, ciprofloxacin; CAZ, ceftazidime; CTX, cefotaxime; FEP, cefepime; PIP,
piperacillin; P ⁄T, piperacillin–tazobactam.
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from ICUs. The isolates from different wards with
similar ERIC-PCR patterns showed different PFGE
patterns. Antibiogram patterns were found to be
unrelated to the genotypes. When MIC values
within two dilutionswere considered to be similar,
the results obtained were inconsistent with those
obtained by genotyping. In addition, variations in
MICs within a genotype were observed, while
isolates with different ERIC-PCR and PFGE pat-
terns sometimes had similar MIC values. Table 4
presents data for 42 isolateswith similar ERIC-PCR
patterns, together with their PFGE patterns, anti-
biogram similarities, and data concerning the
patients from whom they were isolated (including
hospital wards and dates of isolation).
DISCUSSION
S. maltophilia causes infections mainly in hospitals
and is a particular risk for debilitated patients.
This organism is ubiquitous in the environment
and in the hospital setting [4,9]. Since it is able to
grow in many different media in the presence of
most antimicrobial agents, S. maltophilia is isola-
ted with increasing frequency as a nosocomial
pathogen. The annual isolation rate per 10 000
patient discharges rose from 7.1 in 1981 to 14.1 in
1984 at a university hospital in the USA [20]. A
widespread study between 1997 and 2001, inclu-
ding data from Asia-Pacific, Europe and America,
showed that S. maltophilia was the third most
frequently isolated non-fermentative bacterium,
following P. aeruginosa and Acinetobacter, with a
rate of isolation from clinical specimens of 8%
[21]. As described above, the isolation frequency
of S. maltophilia increased during the period of the
present study, but further investigations are
needed to clarify the underlying reasons for this
increase. As in the present study, S. maltophilia is
isolated most often from respiratory specimens
Table 4. Data for 42 isolates of
Stenotrophomonas maltophilia show-
ing their distribution into 17 ERIC-
PCR and 13 PFGE pattern groups,
antibiogram similarities, patients,
hospital wards and isolation dates
ERIC-PCR
pattern no.
PFGE
pattern no. Antibiogram
Isolate
no.
Patient
no. Ward Date
E1 P1 PIP, P ⁄T different 21 H16 ICU 26 ⁄ 2 ⁄ 1999
E1 P1 26 H1 ICU 19 ⁄ 4 ⁄ 1999
E1 P1 51 H1 ICU 20 ⁄ 4 ⁄ 1999
E2 P2 Similar 22 H17 ICU 12 ⁄ 3 ⁄ 1999
E2 P2 23 H18 ICU 15 ⁄ 3 ⁄ 1999
E2 P2 24 H19 ICU 15 ⁄ 3 ⁄ 1999
E3 P14 CAZ different 54 H20 ICU 25 ⁄ 11 ⁄ 1999
E3 P15 56 H21 MW 85 28 ⁄ 8 ⁄ 1999
E4a P3 Similar 64 H22 SICU 27 ⁄ 10 ⁄ 2000
E4b P3 65 H23 SW 51 16 ⁄ 11 ⁄ 2000
E5 P16 Similar 70 H24 MW 76 4 ⁄ 5 ⁄ 2000
E5 P17 71 H25 ICU 3 ⁄ 5 ⁄ 2000
E6 P18 Similar 80 H26 SW 72 28 ⁄ 2 ⁄ 2001
E6 P19 81 H27 SW 73 4 ⁄ 1 ⁄ 2001
E7 P20 Similar 87 H28 SW 53 2 ⁄ 11 ⁄ 2001
E7 P21 89 H29 SICU 6 ⁄ 12 ⁄ 2001
E8 P4 Similar 84 H30 ICU 17 ⁄ 4 ⁄ 2001
E8 P4 85 H31 ICU 29 ⁄ 5 ⁄ 2001
E9 P22 GEN, CIP, PIP, P ⁄T different 93 H32 SW 72 9 ⁄ 2 ⁄ 2002
E9 P23 94 H33 SW 51 12 ⁄ 3 ⁄ 2002
E10a P5 Similar 102 H34 Burn 26 ⁄ 4 ⁄ 2002
E10b P5 103 H35 SW 73 1 ⁄ 5 ⁄ 2002
E11 P6 Similar 111 H2 SICU 7 ⁄ 9 ⁄ 2002
E11 P6 118 H2 SICU 12 ⁄ 10 ⁄ 2002
E11 P7 Similar 113 H3 MW 75 20 ⁄ 9 ⁄ 2002
E11 P7 116 H3 MW 75 4 ⁄ 10 ⁄ 2002
E11 P7 115 H36 SW 52 4 ⁄ 10 ⁄ 2002
E12 P8 CIP different 122 H37 ICU 16 ⁄ 11 ⁄ 2002
E12 P8 123 H38 ICU 19 ⁄ 11 ⁄ 2002
E13a P9a Similar 137 H4 SW 84 10 ⁄ 1 ⁄ 2003
E13b P9b 141 H4 SW 84 31 ⁄ 1 ⁄ 2003
E13b P9c 146 H4 SW 84 7 ⁄ 2 ⁄ 2003
E14 P10 T ⁄ S, GEN different 154 H5 MW 85 4 ⁄ 4 ⁄ 2003
E14 P10 156 H5 MW 85 7 ⁄ 4 ⁄ 2003
E15 P11 Similar 181 H6 SW 74 20 ⁄ 9 ⁄ 2003
E15 P11 190 H6 SW 74 2 ⁄ 11 ⁄ 2003
E16 P12a Similar 185 H7 SW 43 27 ⁄ 9 ⁄ 2003
E16 P12b 186 H7 SW 43 27 ⁄ 9 ⁄ 2003
E16 P12b 187 H7 SW 43 27 ⁄ 9 ⁄ 2003
E17a P13 191, 195 similar 191 H8 ICU 30 ⁄ 10 ⁄ 2003
E17a P13 194 CAZ different 195 H8 ICU 3 ⁄ 11 ⁄ 2003
E17b P24 194 H39 MW 86 3 ⁄ 11 ⁄ 2003
ICU, medical intensive care unit; SICU, surgical intensive care unit; MW, medical ward; SW, surgical ward;
PIP, piperacillin; P ⁄T, piperacillin ⁄ tazobactam; CAZ, ceftazidime; GEN, gentamicin; CIP, ciprofloxacin; T ⁄ S,
co-trimoxazole.
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and blood. Thus, Valdezate et al. [22] described
105 S. maltophilia isolates obtained between 1995
and 1998, 79 of which were from the respiratory
tract and 19 from blood.
Differentiation between S. maltophilia colonisa-
tion and infection may be difficult when
S. maltophilia is not the only organism isolated.
Sattler et al. [23] investigated episodes of infection
from non-respiratory sites and reported that
70.6% of S. maltophilia isolates were from poly-
microbial cultures, which yielded mostly P. aeru-
ginosa and Acinetobacter baumannii. Isolation of
S. maltophilia from polymicrobial cultures may be
related to a true infection, and is an important
consideration in determining initial treatment,
since b-lactamases leaking from S. maltophilia cells
can facilitate the survival of b-lactam-susceptible
microorganisms [24]. The present study found
that S. maltophilia was the only microorganism
isolated after cultivation of 97 (47.3%) specimens.
The most frequent co-isolated microorganisms
from other specimens were P. aeruginosa (24.7%),
Staph. aureus (20.1%), Klebsiella spp. (12.1%), and
Acinetobacter spp. (10.3%). Thus, almost half of the
S. maltophilia isolates were monobacterial and
more likely to be a cause of infection than of
colonisation.
The many risk-factors that predispose to
the development of S. maltophilia infection
include prolonged hospitalisation, especially in
ICUs, consumption of broad-spectrum antibiotics,
malignancy, immune suppression, and a break-
down in mucocutaneous defence barriers (e.g.,
following catheterisation, artificial implants,
tracheostomy, or peritoneal dialysis) [2–4,8,25].
Most of the patients (90.4%) in the present study
had underlying diseases, including 35.1% who
had malignant diseases. These results are in
accordance with previously published data.
S. maltophilia is resistant to a wide spectrum of
antimicrobial agents. Berg et al. [26] investigated
both clinical and environmental isolates, and
showed that the resistance profile of a strain did
not depend on its source. In a worldwide sur-
veillance study that included 1488 isolates
obtained between 1997 and 2001 [21], resistance
to the antimicrobial agents tested was > 50%, with
the exception of co-trimoxazole (5%), gatifloxacin
(5%), levofloxacin (6%), ticarcillin–clavulanate
(14%) and ceftazidime (34%). Similarly, the pre-
sent study found resistance rates of > 60% for
all antimicrobial agents except co-trimoxazole.
When an isolate is identified as S. maltophilia, co-
trimoxazole, ticarcillin–clavulanate, doxycycline,
minocycline and the newer quinolones, such as
ofloxacin, levofloxacin, sparfloxacin and moxi-
floxacin, may be possible options for treatment
[21,27].
Although the NCCLS [13] suggests the use of
dilution methods for testing antimicrobial sus-
ceptibilities of S. maltophilia, the correlation
between in-vitro resistance and the clinical
response is unknown. The incubation time and
temperature for susceptibility testing remain con-
troversial, with an increase in incubation time
influencing the resistance rates of S. maltophilia for
co-trimoxazole, ciprofloxacin, b-lactams and ami-
noglycosides [28]. Garrison et al. [29] demonstra-
ted that if S. maltophilia strains were incubated for
> 24 h, mutants resistant to ticarcillin–clavulanate,
ciprofloxacin and gentamicin, and which shared
PFGE patterns with the susceptible strains, could
emerge. In the present study, the differences
between resistance rates obtained after 24 and
48 h of incubation were significant for co-trim-
oxazole, ciprofloxacin, ceftazidime, cefepime, pip-
eracillin and piperacillin–tazobactam (p < 0.05).
As was observed in this study, S. maltophilia
isolates have high genetic diversity, even when
isolated in a single hospital [10,11,26]. It has been
suggested that most isolates are acquired inde-
pendently rather than as a consequence of cross-
transmission [30]. The present study showed that
strains isolated from different wards and sharing
the same ERIC-PCR patterns were different by
PFGE. Although PFGE is recognised as a more
reliable method for genotyping, ERIC-PCR can
provide useful results if demographic data are
also available. ERIC-PCR is a rapid and easy
method with a lower cost than PFGE.
Cross-infections between patients are rare, but
cannot be eliminated if the patients sharing
isolates with identical PFGE patterns are epidem-
iologically linked [17]. The present study found
that only 42 isolates were genetically related
according to ERIC-PCR, and only 31 according
to PFGE. In some cases, isolates from the same
patient showed different ERIC-PCR and ⁄ or PFGE
patterns. In seven of the 15 patients yielding more
than one isolate from different body sites, the
isolates belonged to different genotypes. Isolates
belonging to the same genotype were mostly
obtained from ICUs. Nosocomial outbreaks
of S. maltophilia infection have been reported
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previously. Garcia de Viedma et al. [12] typed
isolates from seven patients in a neonatology
ward using arbitrary-primed (AP)-PCR, ERIC-
PCR and PFGE, and were able to identify an
index case. Similarly, Davin-Regli et al. [16] found
that two patients from different wards with
isolates which shared an AP-PCR pattern had
been in contact with the same X-ray technician.
However, the present study of a large number of
isolates from a Turkish hospital found that cross-
infections with S. maltophilia were uncommon,
and that minor outbreaks, especially those occur-
ring in ICUs, can be controlled with standard
precautions. Nevertheless, the frequency of isola-
tion of S. maltophilia increased during the 6-year
period of the study, and the management of
infections caused by this bacterium could become
a problem because of the multiresistant pheno-
type of these bacteria.
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